{
    "id": 1167,
    "fullName": "KRAS G12X",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KRAS G12X indicates any KRAS missense mutation that results in replacement of the glycine (G) at amino acid 12 by a different amino acid. KRAS codon 12 variants are hotspot mutations that often interfere with Ras GTPase activity, resulting in downstream pathway activation (PMID: 28666118, PMID: 22589270).",
            "references": [
                {
                    "id": 2097,
                    "pubMedId": 22589270,
                    "title": "A comprehensive survey of Ras mutations in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22589270"
                },
                {
                    "id": 9843,
                    "pubMedId": 28666118,
                    "title": "RAS Proteins and Their Regulators in Human Disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28666118"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "G12X",
    "createDate": "07/27/2014",
    "updateDate": "11/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 157105,
        "transcript": "NM_033360",
        "gDna": "chr12:g.25245349_25245351",
        "cDna": "c.34_36",
        "protein": "p.G12",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 146,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KRAS codon 12 or 13 mutations were correlated with a lack of response to Iressa (gefitinib) in patients with lung adenocarcinoma (PMID: 15696205).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 211,
                    "pubMedId": 15696205,
                    "title": "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15696205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17112,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12579,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Vectibix (panitumumab) did not demonstrate efficacy in patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 (PMID: 18316791; NCT00113763).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 340,
                    "pubMedId": 18316791,
                    "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18316791"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15742,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Salirasib was well tolerated in Japanese patients with advanced solid tumors (n=21), and while the median progression-free survival (PFS) in the study overall was 53 days, patients harboring mutations in codon G12 or G13 of Kras (n=4) had a median PFS of 227 days (PMID: 29992354).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 909,
                "therapyName": "Salirasib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13693,
                    "pubMedId": 29992354,
                    "title": "An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29992354"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1448,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 187,
                    "pubMedId": 23934108,
                    "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23934108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1439,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 1104,
                "therapyName": "Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1282,
                    "pubMedId": 23209813,
                    "title": "KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209813"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4824,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic cancer cell line harboring a KRAS codon 12 mutation demonstrated resistance to PHT-427, resulting in increased Akt activity (PMID: 20197390, PMID: 20418756).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 3148,
                "therapyName": "PHT-427",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3643,
                    "pubMedId": 20418756,
                    "title": "Phenotype and genotype of pancreatic cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20418756"
                },
                {
                    "id": 4754,
                    "pubMedId": 20197390,
                    "title": "Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20197390"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18987,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-3406 inhibited MAPK signaling, resulted in growth inhibition of cancer cell lines harboring KRAS G12X mutations in culture and in cell line xenograft models (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 2019, Abstract PL06-01).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 8871,
                "therapyName": "BI-3406",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16631,
                    "pubMedId": null,
                    "title": "Discovery of BI-3406: a potent and selective SOS1:KRAS inhibitor opens a new approach for treating KRAS-driven tumors",
                    "url": "https://eventpilotadmin.com/web/planner.php?id=AACR19MT"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17098,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with KRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1444,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic cell lines with KRAS codon 12 mutations had increased sensitivity to Binimetinib (MEK162) (PMID: 25167228).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1294,
                    "pubMedId": 25167228,
                    "title": "KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25167228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 141,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KRAS mutations in codon 12 were associated with resistance to Tarceva (erlotinib) in patients with lung adenocarcinoma (PMID: 15696205).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 211,
                    "pubMedId": 15696205,
                    "title": "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15696205"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3265,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1449,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 187,
                    "pubMedId": 23934108,
                    "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23934108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2442,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines with various KRAS codon 12 mutations displayed differential inhibition by PD-0325901 (PMID: 26037647).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3052,
                    "pubMedId": 26037647,
                    "title": "Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26037647"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3312,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929).",
            "molecularProfile": {
                "id": 13163,
                "profileName": "KRAS G12X PIK3CA E545X"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3378,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient harboring a PIK3CA G1049 mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929).",
            "molecularProfile": {
                "id": 13305,
                "profileName": "KRAS G12X KRAS G13X PIK3CA mut"
            },
            "therapy": {
                "id": 3133,
                "therapyName": "Bevacizumab + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3385,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, the combination of Pilaralisib (XL147) plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929).",
            "molecularProfile": {
                "id": 13308,
                "profileName": "KRAS G12X PIK3CA H1047X"
            },
            "therapy": {
                "id": 3135,
                "therapyName": "Carboplatin + Paclitaxel + XL147",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1192,
            "profileName": "KRAS G12X",
            "profileTreatmentApproaches": [
                {
                    "id": 15801,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "KRAS G12X"
                },
                {
                    "id": 15804,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "KRAS G12X"
                },
                {
                    "id": 15805,
                    "name": "MEK1 Inhibitor",
                    "profileName": "KRAS G12X"
                },
                {
                    "id": 15800,
                    "name": "MEK2 Inhibitor",
                    "profileName": "KRAS G12X"
                },
                {
                    "id": 15799,
                    "name": "AZD4785",
                    "profileName": "KRAS G12X"
                },
                {
                    "id": 15802,
                    "name": "PIK3CA inhibitor",
                    "profileName": "KRAS G12X"
                },
                {
                    "id": 15803,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "KRAS G12X"
                }
            ]
        },
        {
            "id": 13163,
            "profileName": "KRAS G12X PIK3CA E545X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13305,
            "profileName": "KRAS G12X KRAS G13X PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13308,
            "profileName": "KRAS G12X PIK3CA H1047X",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 157105,
            "transcript": "NM_033360",
            "gDna": "chr12:g.25245349_25245351",
            "cDna": "c.34_36",
            "protein": "p.G12",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157104,
            "transcript": "NM_004985",
            "gDna": "chr12:g.25245349_25245351",
            "cDna": "c.34_36",
            "protein": "p.G12",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157107,
            "transcript": "XM_011520653",
            "gDna": "chr12:g.25245349_25245351",
            "cDna": "c.34_36",
            "protein": "p.G12",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157108,
            "transcript": "XM_006719069",
            "gDna": "chr12:g.25245349_25245351",
            "cDna": "c.34_36",
            "protein": "p.G12",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157106,
            "transcript": "XM_017019293",
            "gDna": "chr12:g.25245349_25245351",
            "cDna": "c.34_36",
            "protein": "p.G12",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}